Lynn Savoie

968 total citations
25 papers, 523 citations indexed

About

Lynn Savoie is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Lynn Savoie has authored 25 papers receiving a total of 523 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 11 papers in Genetics and 6 papers in Oncology. Recurrent topics in Lynn Savoie's work include Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (6 papers). Lynn Savoie is often cited by papers focused on Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (6 papers). Lynn Savoie collaborates with scholars based in Canada, United States and Denmark. Lynn Savoie's co-authors include Thaddeus J. Unger, Michael R. Savona, Morten Mau‐Sørensen, Nashat Gabrail, Rachid Baz, Tami Rashal, Sharon Shacham, Martin Gutierrez, Michael Kauffman and Richard M. Stone and has published in prestigious journals such as Blood, British Journal of Haematology and Bone Marrow Transplantation.

In The Last Decade

Lynn Savoie

23 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lynn Savoie Canada	11	298	238	170	144	97	25	523
John Liu Yin United Kingdom	6	400 1.3×	169 0.7×	152 0.9×	164 1.1×	97 1.0×	8	530
Lucia Casarino Italy	13	323 1.1×	162 0.7×	131 0.8×	163 1.1×	130 1.3×	26	608
S. Kurtin United States	3	554 1.9×	280 1.2×	77 0.5×	250 1.7×	71 0.7×	8	674
Rama Al Hamed France	9	308 1.0×	236 1.0×	223 1.3×	56 0.4×	71 0.7×	11	487
Keiren Kirkland United Kingdom	11	297 1.0×	84 0.4×	162 1.0×	105 0.7×	83 0.9×	24	458
Anne Stidsholt Roug Denmark	13	286 1.0×	213 0.9×	124 0.7×	133 0.9×	47 0.5×	53	522
Birgitte Preiss Denmark	12	461 1.5×	207 0.9×	143 0.8×	156 1.1×	39 0.4×	25	554
Bianca F. Goemans Netherlands	10	419 1.4×	200 0.8×	85 0.5×	115 0.8×	39 0.4×	34	563
JM Hernández Spain	8	346 1.2×	187 0.8×	115 0.7×	100 0.7×	54 0.6×	12	426
Iman Abou Dalle Lebanon	12	261 0.9×	140 0.6×	107 0.6×	60 0.4×	51 0.5×	46	430

Countries citing papers authored by Lynn Savoie

Since Specialization

Citations

This map shows the geographic impact of Lynn Savoie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn Savoie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn Savoie more than expected).

Fields of papers citing papers by Lynn Savoie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynn Savoie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn Savoie. The network helps show where Lynn Savoie may publish in the future.

Co-authorship network of co-authors of Lynn Savoie

This figure shows the co-authorship network connecting the top 25 collaborators of Lynn Savoie. A scholar is included among the top collaborators of Lynn Savoie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynn Savoie. Lynn Savoie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Novitzky‐Basso, Igor, Eshetu G. Atenafu, Donna L. Forrest, et al.. (2023). Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study. British Journal of Haematology. 203(5). 781–791. 9 indexed citations

Ghosh, Sunita, et al.. (2021). Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI. Leukemia Research. 111. 106674–106674. 3 indexed citations

Kim, Dennis Dong Hwan, Eshetu G. Atenafu, Igor Novitzky‐Basso, et al.. (2021). BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. British Journal of Haematology. 196(1). 136–145. 4 indexed citations

Kim, Dennis Dong Hwan, Igor Novitzky‐Basso, Tae-Hyung Kim, et al.. (2020). Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. Blood. 136(Supplement 1). 54–55. 3 indexed citations

Kim, Dennis Dong Hwan, Isabelle Bence‐Bruckler, Lambert Busque, et al.. (2019). The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up. Blood. 134(Supplement_1). 1644–1644. 1 indexed citations

Bence‐Bruckler, Isabelle, Lambert Busque, Donna L. Forrest, et al.. (2019). Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt. Blood. 134(Supplement_1). 1653–1653.

Bence‐Bruckler, Isabelle, Lambert Busque, Donna L. Forrest, et al.. (2019). BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission. Blood. 134(Supplement_1). 2933–2933. 1 indexed citations

Tay, Jason, Andrew Daly, Kareem Jamani, et al.. (2018). Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables. Bone Marrow Transplantation. 54(3). 368–382. 10 indexed citations

Kim, Dennis, Isabelle Bence‐Bruckler, Donna L. Forrest, et al.. (2017). Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD). Blood. 130. 1622–1622. 7 indexed citations

10.

Kuruvilla, John, Michael R. Savona, Rachid Baz, et al.. (2017). Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 129(24). 3175–3183. 112 indexed citations

11.

Garzon, Ramiro, Michael R. Savona, Rachid Baz, et al.. (2017). A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 129(24). 3165–3174. 102 indexed citations

12.

Haas, Barbara K, et al.. (2015). Tunnelled central venous catheter-related bloodstream infection in Canadian blood stem cell transplant recipients: Associated costs. Canadian Oncology Nursing Journal. 25(3). 311–318. 1 indexed citations

13.

Haas, Barbara K, et al.. (2015). Analysis of costs and benefits of transparent, gauze, or no dressing for a tunnelled central venous catheter in Canadian stem cell transplant recipients. Canadian Oncology Nursing Journal. 25(3). 289–298. 2 indexed citations

14.

Couban, Stephen, Lynn Savoie, Yasser Abou Mourad, et al.. (2014). Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus. Current Oncology. 21(2). 265–309. 14 indexed citations

15.

Bredeson, Christopher, Mei‐Jie Zhang, Afiba Manza‐A. Agovi, et al.. (2008). Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide. Biology of Blood and Marrow Transplantation. 14(9). 993–1003. 70 indexed citations

16.

Stewart, Douglas A., Nizar J. Bahlis, Karen Valentine, et al.. (2006). Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 107(12). 4623–4627. 21 indexed citations

17.

Parkins, Michael D., Nizar J. Bahlis, Christopher Brown, et al.. (2006). Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation. Bone Marrow Transplantation. 38(9). 609–614. 11 indexed citations

18.

Russell, James R., Lynn Savoie, A Chaudhry, et al.. (2006). Allogeneic stem cell transplantation for adult acute leukaemia in CR1 and CR2 with a novel myeloablative conditioning regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total body irradiation and low-dose antithymocyte globulin. Biology of Blood and Marrow Transplantation. 12(2). 7–8. 1 indexed citations

19.

Stewart, Douglas A., Peter Forsyth, Ahsan Chaudhry, et al.. (2004). High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).. Blood. 104(11). 911–911. 4 indexed citations

20.

Savoie, Lynn & James B. Johnston. (2001). Hairy cell leukemia. Current Treatment Options in Oncology. 2(3). 217–224. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact